Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall

Related Content

J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
St. Joseph Aspirin Is First J&J/McNeil Divestiture From 2010 OTC Recalls
In Brief
Rolaids Recall Roils McNeil As Year Of OTC Manufacturing Errors Winds Down
Congress Wants More Answers From J&J On "Phantom Recall"
McNeil Elevates Quality Management In Wake Of Tylenol, Motrin Recall
J&J Expects Sales Loss To Be Skin-Deep, Looks To Skin-Care Lines For Boost
GSK's Quick Warning Of Fake Alli Exemplifies Effective Crisis Management
Tylenol Arthritis Pain Caplets on recall
To Rebuild Zicam, Matrixx Can Tap Into Brand's History, Pharmacists' Regard





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts